ivarmacitinib

Small molecule

Also known as SHR0302

Phase 3underway

Evidence outlook · registrational

Non-Radiographic Axial Spondyloarthritis: registrational readout pending

No completed mid-stage readout is on record. The registry's posted readout date (2024-08-30) has passed without a status update. Check News for topline announcements.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Non-Radiographic Axial Spondyloarthritis
NCT05324631 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-16 – 2024-12-11 · Non-radiographic Axial Spondyloarthritis
What this study did
Other / comorbidity
NCT04957550 · Jiangsu HengRui Medicine Co., Ltd.
2021-08-30 – 2026-12-13 · Psoriatic Arthritis
What this study did
NCT05181137 · Reistone Biopharma Company Limited
2021-11-05 – 2025-03-31 · Ulcerative Colitis
What this study did
NCT05470413 · Reistone Biopharma Company Limited
2022-04-18 – 2024-02-15 · Alopecia Areata
What this study did
NCT04333771 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-31 – 2023-09-21 · Rheumatoid Arthritis
What this study did
NCT04875169 · Reistone Biopharma Company Limited
2021-04-30 – 2023-05-23 · Atopic Dermatitis
What this study did
Phase 2/3 (5)
Other / comorbidity
Ivarmacitinib Treat PMRnot yet recruiting
NCT07941778 · Zhejiang University
2026-12-01 – 2028-12-30 · Polymyalgia Rheumatica (PMR)
What this study did
NCT07814664 · Chinese SLE Treatment And Research Group
2026-10-15 – 2028-09-30 · Systemic Lupus Erthematosus
What this study did
NCT04717310 · Reistone Biopharma Company Limited
2020-12-30 – 2024-07-14 · Atopic Dermatitis
What this study did
NCT04481139 · Jiangsu HengRui Medicine Co., Ltd.
2020-10-14 – 2023-05-12 · Ankylosing Spondylitis
What this study did
NCT04774809 · Reistone Biopharma Company Limited
2020-01-29 – 2022-03-21 · Vitiligo
What this study did
Phase 2 (16)
Other / comorbidity
NCT07505186 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-08-17 – 2033-12-31 · Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
What this study did
NCT07845955 · Huijie Zhang
2026-09-30 – 2029-12-31 · T1DM - Type 1 Diabetes Mellitus
What this study did
NCT07570745 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-05-01 – 2029-05-01 · Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation
What this study did
NCT07324473 · First Affiliated Hospital of Chongqing Medical University
2026-01-01 – 2029-01-01 · Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
What this study did
NCT07313202 · Fujian Cancer Hospital
2025-12-10 – 2028-12-26 · Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
What this study did
NCT07896096 · Renmin Hospital of Wuhan University
2026-04-14 – 2028-06-30 · Refractory Metastatic Colorectal Cancer
What this study did
NCT06925048 · Chunxia Su
2025-04-30 – 2027-12-31 · Non-Small Cell Lung Cancer, JAK Inhibitor, Immunology
What this study did
NCT06731153 · Fudan University
2024-12 – 2027-12 · Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
What this study did
NCT07251595 · Jiangsu HengRui Medicine Co., Ltd.
2025-12-05 – 2027-09 · Non-segmental Vitiligo
What this study did
NCT06519526 · Fudan University
2024-08-12 – 2027-08-31 · Relapsed/Refractory Peripheral T Cell Lymphoma
What this study did
NCT07634848 · Liu Tian
2026-06-01 – 2027-05-31 · Behcet's Syndrome
What this study did
NCT03677648 · Reistone Biopharma Company Limited
2019-05-14 – 2021-12-09 · Crohn's Disease
What this study did
NCT04346316 · Reistone Biopharma Company Limited
2020-05-13 – 2021-06-29 · Alopecia Areata
What this study did
NCT03675477 · Reistone Biopharma Company Limited
2019-04-13 – 2021-02-03 · Ulcerative Colitis
What this study did
NCT04162899 · Reistone Biopharma Company Limited
2019-11-06 – 2020-08-31 · Atopic Dermatitis
What this study did
NCT03254966 · Jiangsu HengRui Medicine Co., Ltd.
2017-11-24 – 2019-10-12 · Rheumatoid Arthritis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07381114 · Institute of Hematology & Blood Diseases Hospital, China
2026-02-14 – 2027-12-30 · aGVHD
What this study did
Phase 1 (13)
Other / comorbidity
NCT05900089 · Henan Cancer Hospital
2023-05-30 – 2026-06-01 · Peripheral T Cell Lymphoma
What this study did
NCT04146207 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2020-04-02 – 2024-10-31 · Chronic GVHD
What this study did
NCT06202612 · Jiangsu HengRui Medicine Co., Ltd.
2024-01-16 – 2024-02-21 · Autoimmune Diseases
What this study did
NCT05856058 · Jiangsu HengRui Medicine Co., Ltd.
2023-05-29 – 2023-10-09 · Graft-versus-host Disease
What this study did
NCT05392127 · Jiangsu HengRui Medicine Co., Ltd.
2022-07-15 – 2022-08-18 · Rheumatoid Arthritis
What this study did
NCT05404724 · Jiangsu HengRui Medicine Co., Ltd.
2022-06-25 – 2022-07-11 · Rheumatoid Arthritis
What this study did
NCT05047341 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-07 – 2022-06-08 · Rheumatoid Arthritis (RA)
What this study did
NCT04712838 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-15 – 2021-04-13 · Healthy Subjects
What this study did
NCT04293029 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-20 – 2020-12-30 · Hepatic Impairment
What this study did
NCT02665910 · Jiangsu HengRui Medicine Co., Ltd.
2016-05 – 2016-12 · Rheumatoid Arthritis
What this study did
NCT02892370 · Jiangsu HengRui Medicine Co., Ltd.
2016-08 – 2016-10 · Rheumatoid Arthritis
What this study did
NCT02423538 · Jiangsu HengRui Medicine Co., Ltd.
2015-04 – 2016-07 · Rheumatoid Arthritis
What this study did
Phase 4 (3)
Other / comorbidity
NCT07894497 · Peking University Third Hospital
2026-10-25 – 2030-07-31 · Ankylosing Spondylitis (AS)
What this study did
NCT07451665 · Chinese SLE Treatment And Research Group
2026-04-01 – 2029-03-31 · Takayasu Arteritis (TAK)
What this study did
NCT07452445 · Tongji Hospital
2026-03-01 – 2029-03-01 · Rheumatoid Arthritis
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT07276620 · Xiangya Hospital of Central South University
2025-11-30 – 2029-01-30 · Atopic Dermatitis (AD)
What this study did
NCT07266168 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-01-20 – 2028-11-30 · Polymyalgia Rheumatics (PMR)
What this study did
NCT07270003 · Xijing Hospital
2025-10-01 – 2026-10-01 · Palmoplantar Pustulosis (PPP)
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 3 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ivarmacitinib: this drugPhase 3Small moleculeJAKnot yet gradedNo reviewed efficacy summary
Baricitinib (Olumiant)
Approved(overall)
Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
Tofacitinib (Xeljanz)
Approved(overall)
Small moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)
Approved(overall)
Small moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Filgotinib (Jyseleca)
Phase 3(overall)
Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
QLM3003
Phase 3(overall)
Small moleculeJAKPartial signalNo reviewed efficacy summary
ZL-82
Phase 2(overall)
Small moleculeJAKWeak signalNo reviewed efficacy summary

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ivarmacitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 3Psoriatic ArthritisActive not recruiting
Est. primary completion 2026-12-13 · NCT04957550 · CT.gov ↗
What to watch
Phase 1/2aGVHDNot yet recruiting
Est. primary completion 2026-12-30 · NCT07381114 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung Cancer, JAK Inhibitor, ImmunologyNot yet recruiting
Est. primary completion 2026-12-31 · NCT06925048 · CT.gov ↗
What to watch
2027 (7)
February 2027 (1)
Phase 2Relapsed/Refractory Peripheral T Cell LymphomaRecruiting
Est. primary completion 2027-02-28 · NCT06519526 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Non-segmental VitiligoRecruiting
Est. primary completion 2027-03 · NCT07251595 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Triple Negative Breast Cancer (TNBC), Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT06731153 · CT.gov ↗
What to watch
Early phase / not applicableAtopic Dermatitis (AD)Not yet recruiting
Est. primary completion 2027-06-30 · NCT07550452 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Refractory Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07896096 · CT.gov ↗
What to watch
Early phase / not applicablePolymyalgia Rheumatics (PMR)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07266168 · CT.gov ↗
What to watch
Phase 2Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAENot yet recruiting
Est. primary completion 2027-12-31 · NCT07313202 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 2Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug RepurposingNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
March 2028 (3)
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2028-03-01 · NCT07452445 · CT.gov ↗
What to watch
Phase 2/3Systemic Lupus ErthematosusNot yet recruiting
Est. primary completion 2028-03-30 · NCT07814664 · CT.gov ↗
What to watch
Phase 2/3Polymyalgia Rheumatica (PMR)Not yet recruiting
Est. primary completion 2028-03-30 · NCT07941778 · CT.gov ↗
What to watch
April 2028 (1)
Early phase / not applicableAtopic Dermatitis (AD)Not yet recruiting
Est. primary completion 2028-04-30 · NCT07276620 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Graft-Versus-Host Disease(GVHD), Bone Marrow TransplantationRecruiting
Est. primary completion 2028-05-01 · NCT07570745 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-12-31 · NCT07505186 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 4Takayasu Arteritis (TAK)Not yet recruiting
Est. primary completion 2029-03-31 · NCT07451665 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2T1DM - Type 1 Diabetes MellitusNot yet recruiting
Est. primary completion 2029-08-31 · NCT07845955 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Ankylosing Spondylitis (AS)Not yet recruiting
Est. primary completion 2029-12-31 · NCT07894497 · CT.gov ↗
What to watch

See the full readout calendar ↗